

Thyroid function and cardiovascular disease: the mediating role of coagulation factors

Arjola Bano, Layal Chaker, Moniek P. M. de Maat, Ferdows Atiq, Maryam Kavousi, Oscar H. Franco, Francesco U. S. Mattace-Raso, Frank W. G. Leebeek, Robin P. Peeters

The Journal of Clinical Endocrinology & Metabolism
Endocrine Society

Submitted: January 09, 2019

Accepted: March 27, 2019

First Online: April 02, 2019

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising from references to, products or publications do not imply endorsement of that product or publication.

Thyroid function, coagulation, and cardiovascular disease

Thyroid function and cardiovascular disease: the mediating role of coagulation factors

Arjola Bano^{1,2,3,4}, Layal Chaker^{1,2}, Moniek P. M. de Maat⁵, Ferdows Atiq⁵, Maryam Kavousi², Oscar H. Franco^{2,3}, Francesco U. S. Mattace-Raso^{1,6}, Frank W. G. Leebeek⁵, Robin P. Peeters^{1,2}

¹Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands Academic Center for Thyroid Diseases, Erasmus Medical Center, Rotterdam, the Netherlands

²Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands

³Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

⁴Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁵Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands

⁶Section of Geriatric Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

ORCID numbers:

0000-0003-0956-7145

Bano

Arjola

Received 09 January 2019. Accepted 27 March 2019.

Context: Mechanisms linking high and high-normal thyroid function to an increased cardiovascular risk remain unclear. Hypothetically, coagulation can play a role.

Objective: To investigate: (i) the association of thyroid function with coagulation factors, (ii) whether coagulation factors mediate the association of thyroid function with cardiovascular disease (CVD).

Design and Setting: Rotterdam Study, a population-based, prospective study

Participants and Main outcome measurements: In 5918 participants (mean age, 69.1 years), we measured thyrotropin, free thyroxine (FT₄) and coagulation factors (von Willebrand factor antigen [VWF:Ag], ADAMTS13 activity, fibrinogen). Participants were followed for the occurrence of cardiovascular events and deaths. Associations of thyroid function with coagulation factors (standardized Z scores) and CVD were assessed through linear regression and Cox-proportional hazard models, adjusted for potential confounders. We performed causal mediation analyses to evaluate if the effect of thyroid function on CVD is mediated by coagulation.

Results: Higher FT₄ levels were associated with higher VWF:Ag ($\beta=0.34$; 95% confidence interval [95% CI]=0.22,0.47), lower ADAMTS13 activity ($\beta=-0.22$; 95% CI=-0.35,-0.09), and higher fibrinogen ($\beta=0.26$; 95% CI=0.13,0.39). 857 incident cardiovascular events and 690 cardiovascular deaths occurred. FT₄ levels were positively associated with cardiovascular events and deaths. The effect of FT₄ on incident cardiovascular events was minimally mediated by fibrinogen (1.6%), but not by VWF:Ag and ADAMTS13. VWF:Ag and fibrinogen together mediated 10.0% of the effect of FT₄ on cardiovascular deaths.

Conclusions: Higher FT₄ levels were associated with higher VWF:Ag, lower ADAMTS13 activity and higher fibrinogen, indicating a procoagulant state. VWF:Ag and fibrinogen explained up to 10% of the link between FT₄ with CVD.

This study investigated whether coagulation factors mediate the role of thyroid function on cardiovascular disease. VWF:Ag and fibrinogen partly explained the link of FT4 with cardiovascular disease. .

Introduction

The cardiovascular system is one of the major targets of thyroid hormone action. Thyroid hormones affect cardiomyocytes by stimulating the ion channels in the cell membranes and by binding to the nuclear thyroid hormone receptors, further promoting the expression of target genes.(1) Thyroid hormones also influence the cardiovascular system by affecting the sympathetic nervous system and the peripheral circulation.(1) To date, population-based studies among middle-aged and older adults have shown that high and high-normal thyroid hormone levels are associated with an increased risk of cardiovascular disease and mortality, independent of traditional cardiovascular risk factors as hyperlipidemia, hypertension, diabetes, and obesity.(2-4) This points towards other factors that can mediate the increased cardiovascular risk in case of excess thyroid hormones. The identification of these mediating factors is essential to better understand the role of thyroid hormones in cardiovascular disease, as well as to identify potential targets for future preventive strategies.

Hemostasis may be one mechanism through which thyroid hormones affect cardiovascular system. *In vitro* and *in vivo* studies have shown that thyroid hormones directly regulate the transcription of genes encoding coagulation proteins in the hepatic and endothelial cells (5-8) (6,9,10). In turn, coagulation proteins, such as von Willebrand factor (VWF), ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motif repeats 13), and fibrinogen have been associated with an increased risk of coronary heart disease (CHD), ischemic stroke(11-14) and cardiovascular mortality.(15) VWF mediates platelet adhesion and aggregation, which play an important role in thrombus formation.(16) ADAMTS13 cleaves the procoagulant VWF multimers into smaller, less procoagulant multimers.(17) Fibrinogen is converted into fibrin, which strengthens the clot structure of the thrombus. Despite the clear role of coagulation factors on cardiovascular system, it has never been investigated whether and to what extent coagulation factors mediate the association of thyroid function with cardiovascular disease and mortality. To date, observational and experimental studies have established an increased risk of bleeding in hypothyroidism and an increased risk of thrombosis in hyperthyroidism.(18,19) However, previous studies have not investigated whether the anticoagulant effects of hypothyroidism and the procoagulant effects of hyperthyroidism are extended even within the normal reference range of thyroid function.

In this large prospective population-based cohort study, we aimed to: (i) assess the association of thyroid function with VWF, ADAMTS13, and fibrinogen; and (ii) investigate whether and to what extent these coagulation factors mediate the association of thyroid function with cardiovascular events and deaths.

Methods

Study population

This study was embedded within the framework of the Rotterdam Study, a large prospective population-based cohort study among the residents of Ommoord, a district of Rotterdam, the Netherlands. The objectives and study design have been extensively described elsewhere.(20) The Rotterdam Study was initiated in 1989, including 7983 participants aged 55 years or older. In 2000, the study was extended with a second cohort of 3011 subjects. Study participants undergo extensive follow-up medical examinations every 3 to 5 years. Baseline measurements for the present study were performed during the third visit of the first cohort (RS I.3, 1997-1999, n=4797) and the first visit of the second (RS II.1, 2000-2001, n=3011) cohort of the Rotterdam Study. A total of 6140 participants had data available on thyroid

function measurements, VWF:Ag, ADAMTS13 activity, and fibrinogen levels. Of these, 5918 were followed for the occurrence of cardiovascular events and deaths. Participants with thyroid function measurements, coagulation data, and complete information on prevalent cardiovascular disease and mortality, were eligible.

The protocols of the Rotterdam Study have been approved by the Medical Ethics Committee of the Erasmus University and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Population Study Act Rotterdam Study. In accordance with the Declaration of Helsinki, all included participants provided written informed consent to participate in the study and to obtain information from their treating physicians.

Assessment of thyroid parameters

Thyroid function was assessed during the third visit of the first cohort (RS I.3) and the first visit of the second (RS II.1) cohort using the same method and assay. Measurements of TSH, and FT₄, were performed in baseline serum samples stored at -80°C using the electrochemiluminescence immunoassay “ECLIA” Roche (Roche Diagnostics International Ltd, Rotkreuz Switzerland). The reference ranges of TSH (0.40 to 4.0 mIU/L) and FT₄ (0.86 to 1.94 ng/dL, alternatively 11 to 25 pmol/L) were determined based on national guidelines and our previous studies.(20) Precision was determined using Elecsys reagents, pooled human sera, and controls in a modified protocol of the Clinical and Laboratory Standards Institute. The intra- and inter-assay coefficients of variations were ≤8.7% for TSH and ≤4.8% for FT₄. Thyroid peroxidase antibodies (TPOAbs) were assessed with the electrochemiluminescence immunoassay Roche for TPOAbs. TPOAbs >35 kU/ml were considered as positive, as recommended by the assay manufacturer.

Assessment of coagulation factors

Von Willebrand factor antigen (VWF:Ag) levels were measured via in-house ELISA, using polyclonal rabbit anti-human VWF antibodies (DakoCytomation, Glostrup, Denmark) for catching and tagging. ADAMTS13 activity was measured in a kinetic assay using the Fluorescence Resonance Energy Transfer Substrate VWF 73 assay.(21) Fibrinogen levels were derived from the clotting curve of the prothrombin time assay using thromborel S as a reagent in an automated coagulation laboratory (ACL 300 Instrumentation Laboratory). VWF:Ag, ADAMTS13 activity, and fibrinogen levels were measured against a reference curve of serial dilutions of normal human plasma, calibrated against the international standard (Siemens).(22)

Assessment of cardiovascular disease

Cardiovascular events were defined as fatal and nonfatal myocardial infarction, other CHD mortality, or stroke, as previously described.(23) Prevalent cardiovascular disease was defined as history of myocardial infarction, stroke, coronary or other arterial revascularization.(23,24) Prevalent cardiovascular disease was assessed through interview and verified in medical records. Data on incident cardiovascular events were collected through linkage of the study database with files from general practitioners and hospital records. Cardiovascular mortality was defined as death due to CHD, cerebrovascular disease or other cardiovascular diseases, as previously described.(2,23) The ascertainment of cardiovascular mortality in the Rotterdam Study has been extensively described in a previous study.(23) In short, information on cardiovascular mortality is obtained from municipality records, general practitioners and reports of medical specialists. As a first step, all deaths in the Rotterdam Study are adjudicated based on ICD-10 codes. Furthermore, two research physicians review all the available clinical information, and ascertain independently the underlying cause of death. All cases are subsequently reviewed and validated by a medical specialist.

Additional measurements

The baseline home interview provided information on medical history, medication use, tobacco smoking, and alcohol consumption. (20) Smoking habits were categorized as current, former and never smoking. Serum glucose and lipid levels were measured using automatic enzymatic procedures (Roche Diagnostics GmbH, Mannheim, Germany). Anthropometric measurements were performed in the research center by trained medical staff. Body mass index was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured in the sitting position on the right arm and calculated as the mean of two measurements using a random-zero sphygmomanometer. Diabetes mellitus was defined as fasting serum glucose level of 7 mmol/L or more, non-fasting plasma glucose level of 11.1 mmol/L or more (when fasting samples were absent) or the use of antidiabetic medications. C reactive protein was measured in nonfasting serum samples that had been kept frozen at -20°C by use of Rate Near Infrared Particle Immunoassay (Image Immunochemistry System; Beckman Coulter). Blood group antigen phenotypes were reconstructed by haplotypes analysis of 4 single nucleotide polymorphisms rs687289, rs507666, rs8176704, and rs8176749, which served as tagging single nucleotide polymorphisms for the O, A1, A2, and B alleles. Occurrence of cancer was determined through general practitioners and by linkage with a nationwide registry of histopathology and cytopathology in The Netherlands, Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA). Two research physicians independently assessed the first date and diagnosis of cancer. Cancer events were classified according to the international classification of diseases 10th edition. In case of discrepancy, consensus was sought or a cancer epidemiologist decided.

Statistical analysis

The associations of thyroid function (TSH and FT₄) with coagulation factors (ie, VWF:Ag, ADAMTS13 activity, and fibrinogen levels) were assessed by using linear regression models. β s were estimated per 1 standard deviation (sd) increase for VWF:Ag, ADAMTS13 activity, and fibrinogen levels. Associations of thyroid function and coagulation factors with incident cardiovascular events and cardiovascular deaths were assessed through Cox-proportional hazard models. We used restricted cubic splines to account for nonlinearity of the associations, but no evidence of nonlinearity was observed. Analyses were adjusted for potential confounders that were selected based on biological plausibility and previous literature. Model 1 was adjusted for age, sex, and cohort. Model 2 was adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, anticoagulant medications and ABO blood group (O vs non-O). For the analyses in which coagulation factors were the exposure and cardiovascular outcomes were the outcome, we additionally adjusted for TSH and FT₄ levels.

To examine the robustness and applicability of our results, we performed several sensitivity analyses on the association between thyroid function and coagulation factors. (I) To account for the potential influence of inflammation and thyroid autoimmunity, we additionally adjusted our analyses for C reactive protein levels and TPOAb positivity, respectively. Moreover, we investigated the association of TPOAb positivity with coagulation factors. (II) We additionally adjusted our analyses for prevalent cardiovascular disease. (III) Thyroid hormones have been associated with the risk of cancer, which is in turn characterized by a hypercoagulable state. (25) To exclude any potential bias caused by presence of cancer, we excluded participants with cancer at baseline (n=292). (IV) We restricted the analysis to participants with thyroid function within the reference range, without past thyroid disease and not using thyroid medications. (V) To test for potential effect modification, we added product interaction terms of the exposure with covariates in the multivariable model. (VI) Due to the biological interaction between VWF and ADAMTS13, we also investigated the association of thyroid function with the combination of VWF:Ag levels and ADAMTS13 activity. We

grouped participants into 9 categories, based on the combinations of VWF:Ag tertiles and ADAMTS13 tertiles. Furthermore, we performed multinomial logistic regression to evaluate the association between FT₄ levels and the 9 combinations of VWF:Ag tertiles and ADAMTS13 tertiles. Individuals who were in the lowest tertile of VWF:Ag and in the highest tertile of ADAMTS13 (category with lowest thrombotic risk) were considered as reference.

We performed a causal mediation analysis, which evaluated whether the effect of FT₄ on incident cardiovascular events and cardiovascular deaths was mediated by coagulation factors (Figure 1). The following paths were tested: the direct effect (effect of the exposure on the outcome through pathways other than the mediator); the indirect effect (effect of the exposure on the outcome via the mediator); the total effect (the sum of direct effect and indirect effect); the proportion mediated (indirect effect/total effect). To test for mediation effects, we used conditional process analysis techniques as described by Hayes.(26) Statistical analyses were conducted using SPSS version 21.

Results

Baseline characteristics of 5918 eligible participants are shown in Table 1. The mean age was 69.1 years (sd, 8.2) and 56.7% were women (Table 1). During a median follow-up of 11.3 (interquartile range, 10.0 to 12.7) years, 857 incident cardiovascular events and 690 cardiovascular deaths occurred.

Thyroid function and coagulation factors

Higher FT₄ levels were associated with higher VWF:Ag (β , 0.34; 95% confidence interval [95% CI], 0.22 to 0.47, per 1ng/dl increase in FT₄), lower ADAMTS13 activity (β , -0.22; 95% CI, -0.35 to -0.09, per 1ng/dl increase in FT₄), and higher fibrinogen levels (β , 0.26; 95% CI, 0.13 to 0.39, per 1ng/dl increase in FT₄) (Table 2). Overall, TSH was not consistently associated with any of the coagulation factors (Table 2). Results remained consistent after additionally adjusting for C reactive protein, TPOAb, prevalent cardiovascular disease, and after excluding participants with cancer at baseline. No evidence of effect modification was observed. TPOAb positivity was not associated with VWF:Ag, ADAMTS13 activity, or fibrinogen (β , -0.01, 95% CI, -0.08 to 0.06; β , -0.02, 95% CI, -0.10 to 0.05; β , -0.03, 95% CI, -0.10 to 0.04, respectively). Results remained similar or became stronger after restricting the analyses to euthyroid participants (Table 2).

In a sensitivity analysis, we investigated the association of FT₄ levels with the 9 combinations of ADAMTS13 tertiles and VWF:Ag tertiles (Figure 2). With increasing FT₄ levels, the odds of being in the highest tertile of VWF:Ag and the lowest tertile of ADAMTS13 (category with highest thrombotic risk) were higher than the odds of being in the reference category (category with lowest thrombotic risk) (odds ratio, 4.1 per 1 ng/dl increase in FT₄) (Figure 2).

Thyroid function, coagulation factors, and cardiovascular disease

In line with our previous data,(2) higher FT₄ levels were associated with an increased risk of incident cardiovascular events (hazard ratio [HR], 2.01, 95% CI, 1.43 to 2.82, per 1 ng/dl increase; alternatively, HR, 1.14, 95% CI, 1.07 to 1.21, per 1 sd increase in FT₄) and cardiovascular deaths (HR, 2.17, 95% CI, 1.53 to 3.09, per 1 ng/dl increase; alternatively, HR, 1.16, 95% CI, 1.08 to 1.23, per 1 sd increase in FT₄) (Table 3). TSH was not associated with cardiovascular outcomes (Table 3). Higher VWF:Ag and fibrinogen levels were associated with an increased risk of incident cardiovascular events (HR, 1.08, 95% CI, 1.01 to 1.15; HR, 1.09, 95% CI, 1.02 to 1.17, per 1 sd increase, respectively) and cardiovascular deaths (HR, 1.16, 95% CI, 1.09 to 1.24; HR, 1.23, 95% CI, 1.15 to 1.31, per 1 sd increase, respectively) (Table 3). Higher ADAMTS13 activity was associated with a decreased risk of

incident cardiovascular events and cardiovascular deaths (HR, 0.92, 95% CI, 0.86 to 0.99; HR, 0.89, 95% CI, 0.82 to 0.97, per 1 sd increase) (Table 3). The association of thyroid function with coagulation factors and cardiovascular outcomes remained similar or became stronger after restricting the analyses to euthyroid participants (Table 3).

The effect of FT₄ on incident cardiovascular events was minimally mediated by fibrinogen (1.6%), but not by VWF:Ag or ADAMTS13 (Table 4). The effect of FT₄ on cardiovascular deaths was partly mediated by VWF (5.4%) and fibrinogen (6.4%), but not by ADAMTS13. Taken together, VWF:Ag and fibrinogen mediated 10.0% of the effect of FT₄ on cardiovascular deaths (Table 4). The mediating effect of VWF:Ag and fibrinogen was 7% among euthyroid participants (Table 4).

Discussion

In this large population-based cohort study, higher FT₄ levels were associated with higher VWF, lower ADAMTS13 activity, and higher fibrinogen levels, which indicate a procoagulant state. Participants with higher FT₄ levels had an increased thrombotic risk. The associations were independent of cardiovascular risk factors, markers of inflammation and thyroid autoimmunity. VWF and fibrinogen mediated up to 10% of the association between FT₄ and cardiovascular disease.

To date, few population-based studies have investigated the association between categories of thyroid function and coagulation factors. High thyroid function has been linked to elevated levels of VWF and fibrinogen.(27,28) One cohort study showed that high FT₄ levels are associated with elevated VWF concentrations,(28) and another cohort study reported an association of low TSH levels with elevated fibrinogen concentrations.(27) However, both studies were based on arbitrary categorizations of thyroid function, thus not being able to account for potential risk variations within categories. Besides VWF and fibrinogen, an additional factor of coagulation that could be influenced by thyroid function is the metalloprotease ADAMTS13. Yet, to our knowledge, no other cohort studies have explored the potential link between thyroid function and ADAMTS13 activity. Against this background, our study provides novel evidence on the association of thyroid function with coagulation, by focusing on the continuous range of TSH and FT₄ levels, beyond the thyroid status categories. Our results support the hypothesis that the procoagulant effects of high thyroid hormones and the anticoagulant effects of low thyroid hormones are extended even within the normal reference range of thyroid function, as a continuum of effects.

We accounted for several mechanisms that could explain the positive association of thyroid function with coagulation. Among others, cancer and/or thyroid autoimmunity could alter both the circulating levels of thyroid hormones and coagulation factors.(29,30) However, the exclusion of cancer patients and the adjustment for TPOAb did not affect our results. Inflammation is another mechanism through which thyroid function could influence coagulation, but additional adjustments for levels of C reactive protein did not change our results. In line, a randomized crossover study found no effect of thyroid hormones on the expression of inflammation-related genes.(31) Taken together, these data suggest that cancer, thyroid autoimmunity and inflammation, do not explain our results.

Several plausible mechanisms may explain the link between thyroid hormones and VWF. Low thyroid function is a well-known cause of acquired von Willebrand disease, which is characterized by low VWF antigen and/or activity. When induced by hypothyroidism, acquired von Willebrand disease is reversed after thyroid hormone replacement therapy, indicating a direct influence of thyroid hormones on VWF.(32) Most likely, thyroid hormones downregulate the synthesis of VWF in the endothelial cells, via controlling the transcription of the VWF gene.(10,33) In particular, an experimental study found that modulation of the VWF gene requires a prolonged exposure to triiodothyronine (ie, two

weeks).(10) This suggests that thyroid hormones can influence the synthesis of VWF not only via the nuclear thyroid hormone receptors, but also via affecting intermediate transcriptional receptors and/or via other mechanisms than receptor mediated gene expression. Previous studies indicate that thyroid hormones can induce the release of VWF via stimulation of the sympathetic nervous system.(34,35) Furthermore, our data suggests that thyroid hormones can attenuate the role of ADAMTS13 in cleaving the procoagulant VWF multimers into less procoagulant forms. Future studies need to confirm our results and further unravel the potential underlying mechanisms.

The association of thyroid hormones with fibrinogen can be explained by the direct action of thyroid hormones on thyroid hormone receptors and corresponding response elements in the promoter region of the fibrinogen gene.(10,33) In a recent study, the administration of triiodothyronine resulted in a rapid modulation of fibrinogen gene, thus indicating that thyroid hormones have immediate effects on the synthesis of fibrinogen.(10) Variations in circulating thyroid hormone levels can also alter fibrin clot structure and lysis.(36) Hypothyroidism has been associated with less compact fibrin networks, enhanced fibrinolysis and low fibrinogen levels; whereas hyperthyroidism has been associated with compact fibrin networks, resistance to fibrinolysis and high fibrinogen levels.(36,37)

Our study showed that VWF and fibrinogen partly mediate the association of FT₄ with cardiovascular disease. The observed proportion of mediation was up to 10%, which is meaningful given the multiple mechanisms through which thyroid hormones affect cardiovascular health. We found no evidence for a mediating role of ADAMTS13. Besides VWF and fibrinogen, other coagulation factors including factors VII, VIII, and IX, can also play a mediating role.(19,28,38,39) Unfortunately, data on these factors were not available in our study. If all relevant coagulation factors could be taken into account in our mediation analyses, the expected proportion of mediation related to coagulation may have been even higher than what we observed in our study.

People with abnormal thyroid hormone levels, past thyroid disease, or using thyroid medications can be prone to fluctuating thyroid hormone levels over time. The fluctuations could further interfere with the evaluation of cardiovascular risk. Instead, people with thyroid function within the normal reference range, without past thyroid disease and not using thyroid medications, have stable thyroid function over time with small intra-individual variation.(40) Importantly, our results remained statistically significant even after restricting the analyses to euthyroid participants, thus indicating the robustness of our findings.

Based on the negative feedback mechanism, the production of FT₄ is tightly regulated by the hypothalamic-pituitary-thyroid axis, with a unique set point for each individual.(41) Our study consistently found an association of FT₄ with coagulation factors. Though not statistically significant, the association of TSH with coagulation factors was generally in the expected opposite direction of FT₄. Other population-based studies among middle-aged and older adults have also reported that FT₄, rather than TSH, is associated with an increased risk of clinical outcomes.(2,4) This may be attributable to the aging process, which reduces the sensitivity of the pituitary gland to thyroid hormones.(42) In order to maintain the same FT₄ levels, older subjects (such as the Rotterdam Study participants) may need different TSH levels compared with younger subjects.

To our knowledge, this is the first population-based cohort study investigating the association of thyroid function with ADAMTS13, and the largest study investigating the association of thyroid function with VWF and fibrinogen. Moreover, this is the first study investigating the potential role of several coagulation factors in mediating the association between thyroid function and cardiovascular disease. Other major strengths are the long term follow-up (maximum follow-up time of almost 15 years), the comprehensive adjudication of

events, and the extensive information on potential confounders. Multiple sensitivity analyses provided consistent findings.

Several limitations should also be mentioned. Thyroid function and coagulation measurements were performed at the same time, and we had no information on the temporal relationship of the association. Nevertheless, current evidence supports an effect of thyroid hormones on coagulation rather than vice-versa.(19) Furthermore, we had no data available on serum triiodothyronine FT₃ levels. This did not allow us to calculate the FT₃/FT₄ ratio, which is considered a useful marker of peripheral thyroxine deiodination. However, we already had data available on TSH and FT₄ levels, which represent the most commonly used measurements of thyroid function in clinical practice. Though we adjusted our analyses for multiple potential confounders, we cannot exclude the possibility of residual or unmeasured confounding. Lastly, the majority of our participants were white middle-aged and older adults. Therefore, the generalizability of our findings to other populations remains unclear.

Conclusions

High and high-normal FT₄ levels among middle-aged and older adults were associated with a procoagulant state. VWF and fibrinogen explained up to 10% of the association between FT₄ and cardiovascular disease. The role of other potential mediators, including coagulation factors VII, VIII, and IX, needs to be examined by further investigations. Future prospective studies are also needed to confirm the temporal association between thyroid function and coagulation factors.

Funding: The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development; the Research Institute for Diseases in the Elderly; the Netherlands Genomics Initiative; the Netherlands Ministry of Education, Culture and Science; the Netherlands Ministry of Health Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Dr. M. Kavousi is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Prof. F.W.G. Leebeek is consultant for UniQure and Shire (fees go to the institution), received unrestricted research grants of CSL Behring and Baxalta (Shire), and travel support from Roche, all outside the submitted work. F. Atiq received research support from CSL Behring. Prof. R.P. Peeters and Dr. L. Chaker are supported by the Netherlands Organization for Health Research and Development Zon-MWTOP grant 91212044 and an Erasmus Medical Center Medical Research Advisory Committee grant. Prof. R. P. Peeters has received lecture fees from IBSA and Goodlife Fertility. The funding sources had no involvement in the collection, analysis, writing, interpretation, nor in the decision to submit the paper for publication.

CSL Behring, Research support, Ferdows Atiq; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NL), VENI 91616079, Maryam Kavousi; Consultant for UniQure and Shire (fees go to the institution), received unrestricted research grants of CSL Behring and Baxalta (Shire), and travel support from Roche, Frank W. G. Leebeek; ZonMw <http://dx.doi.org/10.13039/501100001826>, Zon-MWTOP grant 91212044, Robin P. Peeters; Erasmus Medical Center Medical Research Advisory Committee grant, Robin P. Peeters; IBSA and Goodlife Fertility, Lecture fees, Robin P. Peeters

Address all correspondence and requests for reprints to: Prof. Frank W. G. Leebeek, MD, PhD, Department of Hematology, Erasmus Medical Center, PO box 2040, 3000 CA, Rotterdam, the Netherlands. E-mail: f.leebeek@erasmusmc.nl

Disclosure Summary:

The authors have nothing to disclose.

References

1. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. *Nat Rev Cardiol* 2017; 14:39-55
2. Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, Peeters RP, Kavousi M. Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study. *Circ Res* 2017; 121:1392-1400
3. Pereg D, Tirosh A, Elis A, Neuman Y, Mosseri M, Segev D, Lishner M, Hermoni D. Mortality and coronary heart disease in euthyroid patients. *Am J Med* 2012; 125:826 e827-812
4. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. *J Clin Endocrinol Metab* 2015; 100:1088-1096
5. Lin KH, Lee HY, Shih CH, Yen CC, Chen SL, Yang RC, Wang CS. Plasma protein regulation by thyroid hormone. *J Endocrinol* 2003; 179:367-377
6. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS, Lin KH. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. *Endocrinology* 2004; 145:2804-2814
7. Niessen RW, Pfaffendorf BA, Sturk A, Lamping RJ, Schaap MC, Hack CE, Peters M. The influence of insulin, beta-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells. *Thromb Haemost* 1995; 74:686-692
8. Baumgartner-Parzer SM, Wagner L, Reining G, Sexl V, Nowotny P, Muller M, Brunner M, Waldhausl W. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. *J Endocrinol* 1997; 154:231-239
9. Flores-Morales A, Gullberg H, Fernandez L, Stahlberg N, Lee NH, Vennstrom B, Norstedt G. Patterns of liver gene expression governed by TRbeta. *Mol Endocrinol* 2002; 16:1257-1268
10. Salloum-Asfar S, Boelen A, Reitsma PH, van Vlijmen BJ. The immediate and late effects of thyroid hormone (triiodothyronine) on murine coagulation gene transcription. *PLoS One* 2015; 10:e0127469
11. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 1997; 96:1102-1108
12. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. *Stroke* 2010; 41:2151-2156
13. Willeit P, Thompson A, Aspelund T, Rumley A, Eiriksdottir G, Lowe G, Gudnason V, Di Angelantonio E. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. *PLoS One* 2013; 8:e55175
14. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. *Arterioscler Thromb* 1994; 14:54-59
15. Sonneveld MA, Franco OH, Ikram MA, Hofman A, Kavousi M, de Maat MP, Leebeek FW. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study. *Arterioscler Thromb Vasc Biol* 2016; 36:2446-2451
16. Ruggeri ZM, Ware J. von Willebrand factor. *Faseb J* 1993; 7:308-316
17. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr., Ginsburg D, Tsai HM. Mutations in a member of

the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* 2001; 413:488-494

18. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. *J Clin Endocrinol Metab* 2007; 92:2415-2420
19. Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, Squizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. *Thromb Haemost* 2012; 108:1077-1088
20. Ikram MA, Brusselle GGO, Murad SD, van Duijn CM, Franco OH, Goedegebure A, Klaver CCW, Nijsten TEC, Peeters RP, Stricker BH, Tiemeier H, Uitterlinden AG, Vernooij MW, Hofman A. The Rotterdam Study: 2018 update on objectives, design and main results. *Eur J Epidemiol* 2017; 32:807-850
21. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETs-VWF73, a first fluorogenic substrate for ADAMTS13 assay. *British Journal of Haematology* 2005; 129:93-100
22. Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Scheifflinger F, Koudstaal PJ, Ikram MA, Leebeek FW. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. *Blood* 2015; 126:2739-2746
23. Leening MJ, Kavousi M, Heeringa J, van Rooij FJ, Verkroost-van Heemst J, Deckers JW, Mattace-Raso FU, Ziere G, Hofman A, Stricker BH, Witteman JC. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. *Eur J Epidemiol* 2012; 27:173-185
24. Wieberdink RG, Ikram MA, Hofman A, Koudstaal PJ, Breteler MM. Trends in stroke incidence rates and stroke risk factors in Rotterdam, the Netherlands from 1990 to 2008. *Eur J Epidemiol* 2012; 27:287-295
25. Khan SR, Chaker L, Ruiter R, Aerts JG, Hofman A, Dehghan A, Franco OH, Stricker BH, Peeters RP. Thyroid Function and Cancer Risk: The Rotterdam Study. *J Clin Endocrinol Metab* 2016; 101:5030-5036
26. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-based Approach. New York, NY: The Guilford Press. 2013
27. Dorr M, Robinson DM, Wallaschofski H, Schwahn C, John U, Felix SB, Volzke H. Low serum thyrotropin is associated with high plasma fibrinogen. *J Clin Endocrinol Metab* 2006; 91:530-534
28. Debeij J, van Zaane B, Dekkers OM, Doggen CJ, Smit JW, van Zanten AP, Brandjes DP, Buller HR, Gerdes VE, Rosendaal FR, Cannegieter SC. High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study. *J Thromb Haemost* 2014; 12:839-846
29. Franchini M, Lippi G, Manzato F, Vescovi PP. Thyroid-associated autoimmune coagulation disorders. *J Thromb Thrombolysis* 2010; 29:87-91
30. Hoylaerts MF, Thys C, Arnout J, Vermynen J. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. *Blood* 1998; 91:2810-2817
31. Stuijver DJ, Elbers LP, van Zaane B, Dekkers OM, Spek CA, Gerdes VE, Reitsma PH, Brandjes DP. The effect of levothyroxine on expression of inflammation-related genes in healthy subjects: a controlled randomized crossover study. *Horm Metab Res* 2014; 46:789-793
32. Stuijver DJ, Piantanida E, van Zaane B, Galli L, Romualdi E, Tanda ML, Meijers JC, Buller HR, Gerdes VE, Squizzato A. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. *Haemophilia : the official journal of the World Federation of Hemophilia* 2014; 20:326-332

33. Elbers LP, Moran C, Gerdes VE, van Zaane B, Meijers J, Endert E, Lyons G, Chatterjee VK, Bisschop PH, Fliers E. The Hypercoagulable state in Hyperthyroidism is mediated via the Thyroid Hormone beta Receptor pathway. *Eur J Endocrinol* 2016;
34. Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors. *Endocr Res* 1993; 19:123-133
35. von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. *Eur J Haematol* 2000; 65:357-369
36. Hooper JM, Stuijver DJ, Orme SM, van Zaane B, Hess K, Gerdes VE, Phoenix F, Rice P, Smith KA, Alzahrani SH, Standeven KF, Ajjan RA. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. *J Clin Endocrinol Metab* 2012; 97:1463-1473
37. Stuijver DJ, Hooper JM, Orme SM, Van Zaane B, Squizzato A, Piantanida E, Hess K, Alzahrani S, Ajjan RA. Fibrin clot structure and fibrinolysis in hypothyroid individuals: the effects of normalising thyroid hormone levels. *J Thromb Haemost* 2012; 10:1708-1710
38. Van Zaane B, Squizzato A, Debeij J, Dekkers OM, Meijers JC, Van Zanten AP, Buller HR, Gerdes VE, Cannegieter SC, Brandjes DP. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. *J Thromb Haemost* 2011; 9:1816-1824
39. Franchini M. Hemostatic changes in thyroid diseases: haemostasis and thrombosis. *Hematology* 2006; 11:203-208
40. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. *J Clin Endocrinol Metab* 2002; 87:1068-1072
41. Andersen S, Bruun NH, Pedersen KM, Laurberg P. Biologic variation is important for interpretation of thyroid function tests. *Thyroid* 2003; 13:1069-1078
42. Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. *Endocr Rev* 1995; 16:686-715

Figure 1. DAG for the association of free thyroxine, coagulation factors and cardiovascular outcomes A, free thyroxine; M, coagulation factor; Y, cardiovascular disease; C1, C2, C3, potential confounders

Figure 2. Association of free thyroxine levels with combined ADAMTS 13 and VWF antigen. a. All participants (TN 5918) b. Euthyroid participants (TN 4646). Due to the biological interaction between VWF:Ag and ADAMTS13, multinomial logistic regression was performed to evaluate the association between FT₄ levels and the nine combinations of VWF:Ag tertiles and ADAMTS13 tertiles, with lowest tertile of VWF:Ag and highest tertile of ADAMTS13 as the reference category. Analyses were adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant medications, and blood group. The plots indicate the odds of being in a specific coagulation category rather than in the reference category, per one unit increase in FT₄ levels. For example, for one unit increase in FT₄ levels, the odds of being in the highest tertile of VWF:Ag and lowest tertile of ADAMTS13 (category with highest thrombotic risk) were 4.1 times higher compared with the odds of being in the lowest tertile of VWF:Ag and highest tertile of ADAMTS13 (category with lowest thrombotic risk). Normal reference ranges of thyroid function were defined as serum TSH of 0.4 to 4.0 mIU/L and FT₄ levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with personal history of thyroid disease. **p*<0.05; ***p*<0.0001 Abbreviations: OR, odds ratio; ADAMTS13, a

disintegrin and metalloprotease with thrombospondin motif repeats 13; VWF:Ag, von Willebrand factor antigen; Ref, reference category.

Table 1. Baseline characteristics of 5918 participants

Age, years	69.1 ± 8.2
Female	3356 (56.7)
Smoking	
<i>current</i>	1068 (18.0)
<i>former</i>	2954 (49.9)
<i>never</i>	1896 (32.0)
TSH, mIU/L	1.8 [1.2-2.8]
FT ₄ , ng/dl	1.2 ± 0.2
TPOAb positive	817 (13.3)
Use of thyroid medication	177 (3.0)
Thyroid surgery	131 (2.2)
History of thyroid disease	498 (8.4)
BMI, kg/m ²	26.9 ± 3.9
History of diabetes	774 (13.1)
Total cholesterol, mmol/l	5.7 ± 0.9
Triglycerides, mmol/l	1.5 ± 0.7
Use of lipid-lowering medications	764 (12.9)
Systolic blood pressure, mm Hg	143.2 ± 21.2
Use of antihypertensive medications	1376 (23.3)
Use of anticoagulant medications	1214 (20.5)
Blood group O	2708 (45.8)
C reactive protein, mg/l	1.8 [0.7-3.9]
Prevalent CHD or stroke	691 (11.7)
Prevalent cancer	289 (4.9)
Fibrinogen, g/l	3.9 ± 0.9
VWF:Ag, %	132 ± 58.4
ADAMTS13 activity, %	91.6 ± 17.6

Values for continuous variables are presented as mean ± standard deviation or median [interquartile range].

Values for categorical variables are presented as number (percentage). Abbreviations: TSH, thyroid-stimulating hormone; FT₄, free thyroxine; TPOAb, thyroid peroxidase antibodies (cutoff, 35 kU/ml); BMI, body-mass index; CHD, coronary heart disease; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif repeats 13; VWF:Ag, von Willebrand factor antigen.

Table 2. Association between thyroid function and Z scores of coagulation factors

	All participants (TN 5918)		Euthyroid participants* (TN 4646)	
	β (95% CI)	β (95% CI)	β (95% CI)	β (95% CI)
	Model 1	Model 2	Model 1	Model 2
VWF:Ag				
TSH	-0.02 (-0.05; 0.01)	-0.03 (-0.06; -0.01)	0.00 (-0.05; 0.05)	-0.02 (-0.07; 0.04)
FT ₄	0.29 (0.16; 0.42)	0.34 (0.22; 0.47)	0.30 (0.12; 0.47)	0.34 (0.17; 0.50)
ADAMTS13 activity				
TSH	0.02 (-0.01; 0.05)	0.00 (-0.03; 0.02)	0.06 (0.01; 0.12)	0.03 (-0.02; 0.09)
FT ₄	-0.29 (-0.42; -0.16)	-0.22 (-0.35; -0.09)	-0.42 (-0.60; -0.25)	-0.33 (-0.50; -0.16)
Fibrinogen				
TSH	-0.03 (-0.06; -0.01)	-0.02 (-0.05; 0.01)	-0.04 (-0.09; 0.02)	-0.01 (-0.06; 0.05)
FT ₄	0.34 (0.21; 0.48)	0.26 (0.13; 0.39)	0.34 (0.16; 0.52)	0.25 (0.07; 0.42)

Model 1: age, sex, cohort; Model 2: Model 1, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant medications, and blood group. βs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). βs of FT₄ are denoted per 1 unit increase in FT₄ (ng/dL). *Normal reference ranges of thyroid function were defined as serum TSH of 0.4-4.0 mIU/L and FT₄ levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with personal history of thyroid disease. Abbreviations: TN, total number; TSH, thyroid-stimulating hormone; FT₄, free thyroxine; VWF:Ag, von Willebrand factor antigen; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif repeats 13.

Table 3. Association of thyroid function and coagulation factors with incident cardiovascular events and deaths

	CV events*	CV deaths†
--	------------	------------

	HR (95% CI)	HR (95% CI)
All participants		
Events/Total number	857/5227	690/5918
Thyroid function		
TSH	0.96 (0.89; 1.03)	0.96 (0.88; 1.04)
FT ₄	2.01 (1.43; 2.82)	2.17 (1.53; 3.09)
Coagulation factors (Z scores)[‡]		
VWF:Ag	1.08 (1.01; 1.15)	1.16 (1.09; 1.24)
ADAMTS13	0.92 (0.86; 0.99)	0.89 (0.82; 0.97)
Fibrinogen	1.09 (1.02; 1.17)	1.23 (1.15; 1.31)
Euthyroid participants[#]		
Events/Total number	675/4093	539/4646
Thyroid function		
TSH	0.96 (0.82; 1.12)	0.88 (0.74; 1.05)
FT ₄	2.79 (1.73; 4.49)	3.37 (2.01; 5.64)
Coagulation factors (Z scores)[‡]		
VWF:Ag	1.09 (1.01; 1.17)	1.15 (1.07; 1.24)
ADAMTS13	0.90 (0.83; 0.98)	0.86 (0.78; 0.94)
Fibrinogen	1.11 (1.03; 1.19)	1.21 (1.13; 1.31)


Adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant medications, and blood group.

HRs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). HRs of FT₄ are denoted per 1 unit increase in FT₄ (ng/dL). *Participants with prevalent cardiovascular events were excluded from the analysis. †Additionally adjusted for prevalent cardiovascular disease. ‡Additionally adjusted for TSH and FT₄. #Normal reference ranges of thyroid function were defined as serum TSH of 0.4 to 4.0 mIU/L and FT₄ levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with personal history of thyroid disease. Abbreviations: CV, cardiovascular; TSH, thyroid-stimulating hormone; FT₄, free thyroxine; VWF:Ag, von Willebrand factor antigen; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif repeats 13.

Table 4. Mediation analysis for the association of FT₄ with cardiovascular events and deaths


	Direct effect		Indirect effect		PM (%)
Potential mediator (Z scores of coagulation factors)	β	P value	β	P value	
All participants					
FT₄ and incident cardiovascular events* (Events/Total number 857/5227)					
VWF:Ag	0.657	0.002	0.014	0.2	-
ADAMTS13	0.661	0.001	0.011	0.2	-
Fibrinogen	0.663	0.002	0.011	0.04	1.6
VWF:Ag and fibrinogen	0.651	0.002	0.021	0.06	-
FT₄ and cardiovascular deaths[†] (Events/Total number 690/5918)					
VWF:Ag	0.642	0.004	0.037	0.02	5.4
ADAMTS13	0.674	0.002	0.011	0.35	-
Fibrinogen	0.629	0.004	0.043	0.006	6.4
VWF:Ag and fibrinogen	0.600	0.007	0.066	0.001	10.0
Euthyroid participants[‡]					
FT₄ and incident cardiovascular events* (Events/Total number 675/4093)					
VWF:Ag	0.939	<0.001	0.0206	0.19	-
ADAMTS13	0.938	<0.001	0.028	0.16	-
Fibrinogen	0.945	<0.001	0.017	0.04	1.8
VWF:Ag and fibrinogen	0.925	0.001	0.032	0.04	3.3
FT₄ and cardiovascular deaths[†] (Events/Total number 539/4646)					
VWF:Ag	0.993	0.001	0.040	0.3	3.9
ADAMTS13	1.017	0.001	0.034	0.14	-
Fibrinogen	0.986	0.001	0.046	0.03	4.5
VWF:Ag and fibrinogen	0.945	0.002	0.071	0.008	7.0

Adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, diabetes, total cholesterol, triglycerides, systolic blood pressure, use of antihypertensive or lipid-lowering medications, use of anticoagulant medications, and blood group. *Participants with prevalent cardiovascular events were excluded from the analysis. †Additionally adjusted for prevalent cardiovascular disease. ‡Normal reference ranges of thyroid function were defined as serum TSH of 0.4 to 4.0 mIU/L and FT₄ levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with personal history of thyroid disease. Abbreviations: FT₄, free thyroxine; PM, proportion mediated; VWF:Ag, von Willebrand factor antigen.



ADVANCE ARTICLE

a. All participants



b. Euthyroid participants

